CTNI-15. CLINICAL EFFICACY OF ONC201 IN NEWLY DIAGNOSED DIPG AND IN PREVIOUSLY IRRADIATED PEDIATRIC H3 K27M-MUTANT GLIOMAS

ONC201, an anti-cancer DRD2 antagonist and ClpP agonist, is in Phase II trials for adult H3 K27M-mutant diffuse midline gliomas. In adults, the recommended phase 2 dose (RP2D) of 625mg ONC201 once a week has been established as a biologically active dose that is well tolerated. Radiographic regressi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Neuro Oncol
Huvudupphovsmän: Gardner, Sharon, Koschmann, Carl, Tarapore, Rohinton S, Allen, Jeffrey, Zaky, Wafik, Odia, Yazmin, Hall, Matthew, Daghistani, Doured, Khatib, Ziad, Aguilera, Dolly, MacDonald, Tobey, Fouladi, Maryam, McGovern, Susan, Mueller, Sabine, Kline, Cassie, Vitanza, Nicholas, Lu, Guangrong, Allen, Joshua, Khatua, Soumen
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2020
Ämnen:
Clinical Trials: Non-Immunologic
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650473/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.182
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk